110 related articles for article (PubMed ID: 38805244)
1. An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent.
Alberti M; Poli G; Broggini L; Sainas S; Rizzi M; Boschi D; Ferraris DM; Martino E; Ricagno S; Tuccinardi T; Lolli ML; Miggiano R
Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):386-396. PubMed ID: 38805244
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
[TBL] [Abstract][Full Text] [Related]
3. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.
Sainas S; Pippione AC; Lupino E; Giorgis M; Circosta P; Gaidano V; Goyal P; Bonanni D; Rolando B; Cignetti A; Ducime A; Andersson M; Järvå M; Friemann R; Piccinini M; Ramondetti C; Buccinnà B; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
J Med Chem; 2018 Jul; 61(14):6034-6055. PubMed ID: 29939742
[TBL] [Abstract][Full Text] [Related]
4. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
Sainas S; Giorgis M; Circosta P; Gaidano V; Bonanni D; Pippione AC; Bagnati R; Passoni A; Qiu Y; Cojocaru CF; Canepa B; Bona A; Rolando B; Mishina M; Ramondetti C; Buccinnà B; Piccinini M; Houshmand M; Cignetti A; Giraudo E; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
J Med Chem; 2021 May; 64(9):5404-5428. PubMed ID: 33844533
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the function and inhibition of dihydroorotate dehydrogenase from Schistosoma mansoni.
de Mori RM; Aleixo MAA; Zapata LCC; Calil FA; Emery FS; Nonato MC
FEBS J; 2021 Feb; 288(3):930-944. PubMed ID: 32428996
[TBL] [Abstract][Full Text] [Related]
7. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
[TBL] [Abstract][Full Text] [Related]
8. Structural and Functional Analyses of Inhibition of Human Dihydroorotate Dehydrogenase by Antiviral Furocoumavirin.
Nakahara M; Watanabe S; Sato M; Okumura H; Kawatani M; Osada H; Hara K; Hashimoto H; Watanabe K
Biochemistry; 2024 May; 63(10):1241-1245. PubMed ID: 38724483
[TBL] [Abstract][Full Text] [Related]
9. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
11. Development of a human dihydroorotate dehydrogenase (hDHODH) pharma-similarity index approach with scaffold-hopping strategy for the design of novel potential inhibitors.
Shih KC; Lee CC; Tsai CN; Lin YS; Tang CY
PLoS One; 2014; 9(2):e87960. PubMed ID: 24504131
[TBL] [Abstract][Full Text] [Related]
12. Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor.
Alberti M; Sainas S; Ronchi E; Lolli ML; Boschi D; Rizzi M; Ferraris DM; Miggiano R
FEBS Lett; 2023 Aug; 597(16):2119-2132. PubMed ID: 37278160
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases.
Davies M; Heikkilä T; McConkey GA; Fishwick CW; Parsons MR; Johnson AP
J Med Chem; 2009 May; 52(9):2683-93. PubMed ID: 19351152
[TBL] [Abstract][Full Text] [Related]
14. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
Lolli ML; Sainas S; Pippione AC; Giorgis M; Boschi D; Dosio F
Recent Pat Anticancer Drug Discov; 2018; 13(1):86-105. PubMed ID: 29119937
[TBL] [Abstract][Full Text] [Related]
15. Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study.
Galati S; Sainas S; Giorgis M; Boschi D; Lolli ML; Ortore G; Poli G; Tuccinardi T
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744791
[TBL] [Abstract][Full Text] [Related]
16. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites.
Walse B; Dufe VT; Svensson B; Fritzson I; Dahlberg L; Khairoullina A; Wellmar U; Al-Karadaghi S
Biochemistry; 2008 Aug; 47(34):8929-36. PubMed ID: 18672895
[TBL] [Abstract][Full Text] [Related]
17. The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.
Deng X; Matthews D; Rathod PK; Phillips MA
Acta Crystallogr F Struct Biol Commun; 2015 May; 71(Pt 5):553-9. PubMed ID: 25945708
[TBL] [Abstract][Full Text] [Related]
18. The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors.
Bonomo S; Tosco P; Giorgis M; Lolli M; Fruttero R
J Mol Model; 2013 Mar; 19(3):1099-107. PubMed ID: 23143678
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase from Y strain.
Pinheiro MP; Iulek J; Cristina Nonato M
Biochem Biophys Res Commun; 2008 May; 369(3):812-7. PubMed ID: 18302934
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases.
Bedingfield PT; Cowen D; Acklam P; Cunningham F; Parsons MR; McConkey GA; Fishwick CW; Johnson AP
J Med Chem; 2012 Jun; 55(12):5841-50. PubMed ID: 22621375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
